Brought to you by 
Roche signs new deal with PTC, this time in the area of spinal muscular atrophy
01 Apr 2021
Executive Summary
Roche has received exclusive worldwide rights to genetic disorder biotech PTC Therapeutics Inc.’s program for the rare muscle weakening disease spinal muscular atrophy. The deal includes three preclinical small molecules, which could enter human testing within 18 months, plus back-up compounds.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche signs new deal with PTC, this time in the area of spinal muscular atrophy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice